Dr Ghazala Sadiq has a PhD in Materials Chemistry from the University of Manchester. She then went on to do a postdoc with Prof Roger Davey’s group in the Department of Chemical Engineering working with pharmaceutical companies including Astra Zeneca, Pfizer, Bayer, Sanofi-Aventis, and Glaxo SmithKline. Ghazala has worked with chemists and engineers across the academic and industry boundary in the context of pharmaceutical and material science research and has acquired a good understanding of drug development processes and solid state chemistry. Her research has been particularly focused on the area of Crystal Engineering, covering a range of topics including polymorphism, co-crystal design, fundamentals of intermolecular interactions, crystallisation, the role of solution chemistry and the importance of molecular self-assembly in the nucleation of crystalline phases. Ghazala is a member of the Royal Society of Chemistry and sits on the BACG (British Association for Crystal Growth) and BCA Industrial Group committee.
Ghazala joined the CCDC in January 2014 as a Pfizer Design Centre Scientist within the Materials Science team. Her role includes applying the latest knowledge-based techniques to drug development compounds. She works closely with Pfizer-based scientists, using knowledge extracted from the Cambridge Structural Database to assess live drug candidates for issues relating to polymorphism, stability and solid form selection. Ghazala also provides scientific support for the small molecule user community.